Form 4: Fulcrum Therapeutics Principal Accounting Officer Acquires Stock Options
SEC Form 4 Filing
Gregory Tourangeau, Principal Accounting Officer of Fulcrum Therapeutics, acquired stock options on January 24, 2025.
Summary
- On January 24, 2025, Gregory Tourangeau, the Principal Accounting Officer of Fulcrum Therapeutics, Inc., was granted stock options to purchase 76,120 shares of common stock at an exercise price of $4.16 per share.
- The options vest in equal quarterly installments over four years, starting January 1, 2025, contingent upon continued service.
Sentiment
Score: 5
Explanation: This is a routine disclosure of stock option grants, neither particularly positive nor negative.
Future Outlook
The stock options vest over a four-year period, contingent on the reporting person's continued service.
Industry Context
Form 4 filings are standard disclosures required by the SEC to report changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The grant of stock options aligns the interests of the Principal Accounting Officer with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 01/01/2025 | Vesting commencement date for the stock options. |
| 01/24/2025 | Date of the stock option grant. |
| 01/28/2025 | Date of signature on the Form 4 filing. |
| 01/23/2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.